Results for: Neurological Diseases

Danish pharmaceutical giant H. Lundbeck A/S has announced the acquisition of Longboard Pharmaceuticals, Inc. in a deal valued at approximately $2.6 billion. The acquisition, expected to close in the fourth quarter of 2024, brings Longboard’s promising neurological disease treatments, particularly bexicaserin, into Lundbeck’s portfolio. This strategic move strengthens Lundbeck’s position in the neurological disease market and diversifies its revenue streams.

Scientists have created miniature models of the human brain that include the organ’s protective blood-brain barrier (BBB). The models, which are about the size of a sesame seed, could be used to study neurological diseases and develop new treatments.